abstract |
The present invention relates to the use of iota- and / or kappa carrageenan for the manufacture of an antiviral pharmaceutical composition for the prevention or treatment of a pathological condition or disease caused by or associated with infection with a selected respiratory virus. from the group consisting of orthomyxoviruses, paramyxoviruses, adenoviruses and coronaviruses. The present invention also relates to the use of fucoidan, especially high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prevention or treatment of a pathological condition or disease caused by or associated with infection with an respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus |